Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T20:36:58.062Z.
Calculation as of: 2026-10-06T20:36:58.062Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3ba604bfa669edc564cc368ab96d70220aa63ab01e3d3e65254ff63c7dd77471
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$139.84M
EV/FCF Ratio
N/A
TTM Avg
31.12x
3Y Avg
31.12x
5Y Avg
31.12x
Market Cap
$137.80M
EV/FCF Ratio
503.85x
TTM Avg
1051.55x
3Y Avg
1051.55x
5Y Avg
1051.55x
Market Cap
$143.84M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immuneering Corporation (IMRX) | $139.04M | N/A | N/A | N/A | N/A |
| Alpha Cognition Inc (ACOG)vs › | $139.47M | N/A | N/A | N/A | N/A |
| Sutro Biopharma, Inc. (STRO)vs › | $139.84M | N/A | 31.12x | 31.12x | 31.12x |
| KORU Medical Systems, Inc. (KRMD)vs › | $137.80M | 503.85x | 1051.55x | 1051.55x | 1051.55x |
| Atrium Therapeutics, Inc. (RNA)vs › | $136.67M | N/A | N/A | N/A | N/A |
| Organigram Global Inc. (OGI)vs › | $136.57M | N/A | N/A | N/A | N/A |
| Nyxoah S.A. (NYXH)vs › | $143.10M | N/A | N/A | N/A | N/A |
| Protara Therapeutics, Inc. (TARA)vs › | $143.60M | N/A | N/A | N/A | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $143.84M | N/A | N/A | N/A | N/A |
| Freenome, Inc. (FRNM)vs › | $133.45M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
